Ipamorelin
Ipamorelin is a lab-made peptide that releases GH in test systems[3]. The UK 2826/en search brief from 2026-08-30 is led by the CJC 1295/ipamorelin pair at 4400 monthly searches. GSRS records the INN IPAMORELIN, UNII Y9M3S784Z6, CAS 170851-70-4, and NNC aliases[1]. The exact PubMed trial search returned two papers[4]. One 40-man study measured GH release[5]. One 117-person bowel-surgery trial found no key effect difference from placebo[6].
The 40-man study found GH release at all five infusion levels and a GH peak at 0.67 hours[5]. The bowel-surgery trial found median first meal at 25.3 hours on the active drug and 32.6 hours on placebo, with p = 0.15[6]. Treatment-emergent events were reported in 87.5% of the active group and 94.8% of the placebo group[6]. The 320-person phase 2 registry record posts no results[8]. The exact PubMed trial search for the CJC-1295 pair returned zero records[10].
What is Ipamorelin?
The name is not enough to prove what is inside a vial. The test section below covers direct checks of material sold or sent in as this peptide.
What has been published in humans?
Human papers exist. They are narrow. One paper measured GH and drug levels in healthy men. One paper tested gut recovery after bowel surgery.
| Source | People and design | Measured result | Funder or source note | Checked |
|---|---|---|---|---|
| [5] | The study used five IV infusion levels with eight healthy men at each level[5]. | The peptide induced GH release at all dose levels. GH peaked at 0.67 hours. The terminal half-life was 2 hours. | PubMed XML lists no grant. The accessible first affiliation is State University of New York at Buffalo. | 2026-08-30 |
| [5] | The study measured the peptide and GH in blood[5]. | Clearance was 0.078 L/h/kg. Volume at steady state was 0.22 L/kg. The model estimated SC50 at 214 nmol/L and peak GH output at 694 mIU/L/h. | PubMed XML lists no grant. The abstract does not report side-effect results. | 2026-08-30 |
| [6] | The phase 2 trial enrolled 117 hospital patients after small or large bowel resection[6]. | The safety and modified intent-to-treat groups included 114 patients. Median first meal was 25.3 hours on the drug and 32.6 hours on placebo. The comparison was p = 0.15. | ClinicalTrials.gov names Helsinn Therapeutics as sponsor for NCT00672074[7]. PubMed indexes the paper as Research Support, Non-U.S. Gov't. | 2026-08-30 |
| [6] | The same trial checked side effects and lab tests[6]. | Treatment-emergent events occurred in 87.5% of the active group and 94.8% of the placebo group. The authors found no significant differences in key and secondary efficacy checks. | ClinicalTrials.gov names Helsinn Therapeutics as sponsor for NCT00672074[7]. | 2026-08-30 |
| [8] | The separate phase 2 registry record enrolled 320 participants and completed in May 2014[8]. | The registry posts no results section. The registry links no results paper in the fields checked. | Helsinn Therapeutics was the sponsor. | 2026-08-30 |
| [9] | The Trifecta Research Study enrolled 52 people and includes the peptide inside a bundled supplement block[9]. | The design cannot isolate the peptide from testosterone, anastrozole, gonadorelin, vitamins, amino acids, fish oil, psychedelics, or magnetic e-resonance therapy. | Axial Therapeutic Research is the sponsor. | 2026-08-30 |
No published human trial result cited here measured muscle gain, gym recovery, sleep, fat loss, or healthy ageing as an outcome for the peptide. The exact PubMed clinical-trial search returned two papers, and both are described in the table above[4].
What does the evidence say about ipamorelin with CJC-1295?
The measured search demand for this page is led by the pair. The UK 2826/en brief measured 21400 monthly searches in the CJC 1295/ipamorelin family on 2026-08-30. The top three pair phrases were each measured at 4400 monthly searches.
Controlled trial evidence has not caught up with that search shape. The exact PubMed trial search for the pair returned zero records[10]. The human papers cited here did not test CJC-1295. The CJC-1295 register page separately covers CJC-1295 with DAC, CJC no-DAC naming, and the CJC-1295 human evidence.
User reports discuss combined labels. One ExcelMale thread follows a 2014 account that used this peptide with products labelled CJC-1295 without DAC and later added a DAC-labelled exposure[19]. A Reddit thread contains positive CJC/Ipa reports and a separate rash report involving CJC-1295[20]. Those reports are self-reported and self-selected. They are not lab proof of either product.
What side effects and safety findings were recorded?
The strongest human result on this page is GH release in healthy men. The same record also needs the safety facts and gaps beside it. The table keeps studies, FDA statements, and one case report separate.
| Source | Recorded finding | Limit | Funding or authority note | Checked |
|---|---|---|---|---|
| [5] | The accessible abstract reports no side-effect result[5]. | The paper measured PK and GH response after short IV exposure. | PubMed XML lists no grant. | 2026-08-30 |
| [6] | Treatment-emergent events occurred in 87.5% of the active group and 94.8% of the placebo group[6]. | The abstract does not give a full event table by type. | ClinicalTrials.gov names Helsinn Therapeutics as sponsor for NCT00672074[7]. | 2026-08-30 |
| [6] | The authors concluded that the drug was well tolerated and that efficacy checks did not differ significantly from placebo[6]. | The study was small and enrolled patients with a broad range of conditions. | ClinicalTrials.gov names Helsinn Therapeutics as sponsor for NCT00672074[7]. | 2026-08-30 |
| [13] | FDA lists the acetate form under 503B category 2 and again in the withdrawn-nominations table[13]. | This is a US compounding-source statement. It is not a global regulatory verdict. | United States regulator. | 2026-08-30 |
| [13] | FDA names clumping, peptide-related impurities, unnatural amino acids, and API identity concerns for the acetate form[13]. | FDA also says it lacks safety-related information for certain other injection routes. | United States regulator. | 2026-08-30 |
| [13] | FDA says one literature study identified serious adverse events including death when the peptide was given by vein for gastric motility[13]. | The PubMed abstract of the opened published IV gastric-motility trial does not mention death[6]. | United States regulator plus PubMed abstract. | 2026-08-30 |
| [21] | One indexed case report names the peptide once among many substances used by a 34-year-old bodybuilder[21]. | The authors attributed death to genetic predisposition and long-term and recent anabolic-androgenic steroid use, not to the peptide. | PubMed XML lists no grant and the paper declares no conflict of interest. | 2026-08-30 |
What dosage information do sources report for Ipamorelin?
These rows are source reports. They are not advice from this page. A named source matters more than a vial label. No row turns a number into a plan.
| Source | Reported amount | Source type | What that means here | Checked |
|---|---|---|---|---|
| [5] | The study used 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes[5]. | Human PK/PD study | These were research infusion levels in healthy men. | 2026-08-30 |
| [6] | The trial gave 0.03 mg/kg of the active drug or placebo twice daily from day 1 to day 7 after surgery or hospital discharge[6]. | Human phase 2 trial | This was inpatient bowel-surgery research. | 2026-08-30 |
| [8] | The registry names IV active drug and IV saline but posts no dose field in the record checked[8]. | Trial registry | It adds status, sponsor, and population, not a reported amount. | 2026-08-30 |
| [14] | The exact DailyMed search returned zero current US labels for Ipamorelin[14]. | US product-label search | No approved-product dose is supplied by this exact search. | 2026-08-30 |
| [19] | One user reported 100 mcg of the peptide at first, later 100 mcg with 100 mcg CJC-1295, later 200 mcg at three times, and later 400 mcg at night with CJC-labelled products[19]. | Opened user-report thread | This is one self-reported account. The products were not lab verified in the thread. | 2026-08-30 |
The dosage-search demand is large because readers meet the name as a vial label and as a CJC 1295/ipamorelin pair before they find a clean source ledger. The useful answer is a list of named-source amounts. It does not collapse study arms, registry gaps, and forum reports into one usual dose.
What do animal and laboratory studies add?
Animal and lab work explains why human researchers expected GH and gut effects. It also stays separate from human outcomes.
| Source | Finding | Limit | Funder note | Checked |
|---|---|---|---|---|
| [3] | The peptide released GH from primary rat pituitary cells with potency and efficacy similar to GHRP-6[3]. | This is cell work, not a human outcome. | PubMed XML lists no grant. The author affiliation is Novo Nordisk. | 2026-08-30 |
| [3] | In conscious swine, the peptide released GH with ED50 2.3 nmol/kg and Emax 65 ng GH/mL plasma[3]. | Swine hormone response does not establish a human body-composition result. | PubMed XML lists no grant. The author affiliation is Novo Nordisk. | 2026-08-30 |
| [3] | In swine, the peptide did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release[3]. | This is an animal selectivity finding. | PubMed XML lists no grant. The author affiliation is Novo Nordisk. | 2026-08-30 |
| [11] | Adult female rats had dose-dependent bone growth from 42 microm/day in vehicle to 44, 50, and 52 microm/day in treated groups[11]. | The authors said future human studies would be needed for children with growth delay. | PubMed XML lists no grant. The author affiliation is Novo Nordisk. | 2026-08-30 |
| [12] | In male rats after laparotomy and bowel handling, a single dose decreased time to first bowel movement[12]. | The paper used a rodent postoperative-ileus model. | PubMed XML lists no grant. | 2026-08-30 |
| [12] | Repeat dosing in the same rodent model increased fecal output, food intake, and body-weight gain[12]. | The finding helped explain the later bowel-surgery trial, but it is not a human result. | PubMed XML lists no grant. | 2026-08-30 |
What has direct vial or product testing found?
Direct product tests ask whether a sample matches a label. They do not prove a human effect. They do not prove sterility unless sterility was tested.
| Source | What was measured | What was not measured | Funder note | Checked |
|---|---|---|---|---|
| [17] | Danish authorities submitted unknown powders for LC-HRMS analysis, and reference standards identified analogues of GHRP-2, GHRP-6, this peptide, and modified GRF 1-29[17]. | The abstract does not print how many preparations of this peptide were tested. | PubMed XML lists no grant. | 2026-08-30 |
| [17] | In all cases, the detected change was an added glycine amino acid at the N-terminus[17]. | The paper is seized-material testing, not a market survey. | PubMed XML lists no grant. | 2026-08-30 |
| [18] | The preprint worked from voluntary testing reports across 14 peptides and reports 6 identity failures for this peptide[18]. | The opened text gives no denominator or percentage for that identity-failure count. | The manuscript states no outside funding and no conflicts of interest. | 2026-08-30 |
| [18] | Under the authors' manufactured-standards model, 34.2% of reports for this peptide met both the amount and purity criteria[18]. | The preprint is not peer reviewed. Its thresholds are comparison models, not official release decisions. | The manuscript states no outside funding and no conflicts of interest. | 2026-08-30 |
| [18] | Across the full dataset's endotoxin subset, 74 samples had no detectable endotoxin, 133 were below the lower limit, and 36 had low measurable endotoxin from 0.5 to 40 EU/mL[18]. | The opened text does not state an endotoxin count for this peptide alone. | The manuscript states no outside funding and no conflicts of interest. | 2026-08-30 |
The vial-testing guide keeps five questions apart: label, amount, purity, endotoxin, and sterility. The sterility guide covers the sterile-use question that purity tests do not answer.
What do user reports add?
User reports are public self-reports. They show real user speech about goals, pairs, timing, and side effects that controlled papers often do not study. They are self-selected. They are not lab proof. They are not counted here as consensus.
The opened ExcelMale thread follows one 2014 account using products labelled CJC-1295 without DAC and this peptide[19]. The user wrote "Workouts are excellent" after the first report and "could NOT sleep" after a pre-bed report. Later posts described strength gains, great sleep, flushing, and changing amounts. No lab report in the thread confirms either product.
One opened Reddit thread from 27 February 2025 shows positive and adverse self-reports about peptide use, including CJC/Ipa comments[20]. These are direct Reddit quotes from opened comments, linked so the complete thread stays visible.
Everything works better on CJC/Ipa. Immune system, recovery, sex drive, deeper sleep, cognitive function, skin glow, hair.
I loved it!! I did 2 3-month cycles last year, and I had great consistent energy, very fast recovery from the gym, very noticeable muscle gains while losing 15lbs of fat, great sleep, great skin, enhanced cognitive function, much better mood. 41yo F
Ipamorelin and Tesamorelin might have helped me lose body fat, but it could have also been the calorie deficit so IDK.
Not for me- I had an allergic reaction to CJC-1295 (widespread rash) that took a steroid to go away, and MOTS-C which I loved, but caused a big itchy welt after a few weeks of use.
There is no single verdict from these posts. People report energy, recovery, sleep, body changes, fat-loss uncertainty, poor sleep, flushing, and rash. The page keeps those reports apart from the measured GH-release study and the bowel-surgery trial.
What is the current evidence status, and what is the regulatory status?
Tier, trial status, label status, FDA compounding status, and test status are separate flags. A regulator zero is not the same thing as a human-evidence absence. A trial result is not an approval.
| Question | Current answer | Source and limit | Checked |
|---|---|---|---|
| Evidence tier | The record has tier B human evidence because the exact PubMed clinical-trial search returned two randomized clinical-trial papers[4]. | One paper is a short hormone PK/PD study. The other is a bowel-surgery trial. | 2026-08-30 |
| Marketed-use evidence | No cited published human result measured muscle gain, gym recovery, sleep, fat loss, or healthy ageing as an outcome for this peptide. | The exact PubMed clinical-trial search returned only PMID 10496658 and PMID 25331030[4]. | 2026-08-30 |
| Controlled combination evidence | The exact PubMed clinical-trial search for the CJC-1295 pair returned zero records[10]. | Forum accounts discuss combined labels, but controlled papers cited here do not test the pair. | 2026-08-30 |
| Registered trial without results | NCT01280344 is completed, enrolled 320 people, names gastrointestinal dysmotility, lists Helsinn Therapeutics as sponsor, and posts no results[8]. | The record gives no reason for the missing results. | 2026-08-30 |
| Observational registry record | NCT07717866 includes the peptide inside a bundled supplement block[9]. | It cannot isolate an effect from that single item. | 2026-08-30 |
| FDA product-label search | DailyMed's exact Ipamorelin search returned zero current labels[14]. | Exact-name label search only. | 2026-08-30 |
| FDA application search | The exact openFDA brand-name search returned no matching application[15]. | Exact brand-name search only. | 2026-08-30 |
| FDA compounding status | FDA lists the acetate form in 503B category 2 and again in the withdrawn-nominations table[13]. | This is a US pharmacy-compounding source, not a global regulatory status. | 2026-08-30 |
| EMA central medicines report | The EMA central medicines report downloaded on 2026-08-30 had zero ipamorelin text hits in the shared-string scan[16]. | This checks the central EU route. It does not check every national route. | 2026-08-30 |
| Product testing | Seized-powder testing found glycine-modified analogues, and the 2026 preprint reports 6 identity failures for this peptide[17]. | Neither source proves what is in a reader's vial. | 2026-08-30 |
The data file is /data/register.json.
See also
- Full Ipamorelin guide - read the earlier guide and same-compound background.
- CJC-1295 register record - compare the other compound in the measured CJC 1295/ipamorelin search pair.
- Training and recovery hub - compare human and product-testing evidence across related compounds.
- Vial-testing guide - separate label identity from measured contents.
- Sterility guide - separate purity, endotoxin, and sterile-use questions.
- Modified GRF 1-29 register record - compare a separate GHRH-pathway record.
- Sermorelin register record - compare another growth-hormone-axis compound.
- TB-500 register record - compare a combination partner named in the same keyword brief.
- BPC-157 register record - compare a combination partner named in the same keyword brief.
References
- ↑ a b c d NCATS GSRS. Names endpoint. GSRS names. Used for INN, WHO-DD name, display name, and NNC aliases. Checked 2026-08-30.
- ↑ NCATS GSRS. Codes endpoint. GSRS codes. Used for UNII and CAS. Checked 2026-08-30.
- ↑ a b c d e f g h Raun K et al. First selective GH secretagogue. Eur J Endocrinol, 1998. PMID 9849822. DOI 10.1530/eje.0.1390552. Used for identity, rat cell work, rat and swine GH findings, and ACTH/cortisol selectivity. Novo Nordisk affiliation and no PubMed XML grant checked 2026-08-30.
- ↑ a b c d e NLM. Exact PubMed clinical-trial search, run 2026-08-30. Used for the two-record result and bounded marketed-use absence. Checked 2026-08-30.
- ↑ a b c d e f g h i j k Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Human PK/PD study. Pharm Res, 1999. PMID 10496658. DOI 10.1023/a:1018955126402. Used for 40 healthy men, five infusion levels, GH peak, half-life, clearance, volume, SC50, peak GH output, study amounts, and abstract safety gap. No grant in PubMed XML; checked 2026-08-30.
- ↑ a b c d e f g h i j k l m n Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Bowel-surgery trial. Int J Colorectal Dis, 2014. PMID 25331030. DOI 10.1007/s00384-014-2030-8. Used for design, population, amount, 117 enrolled, 114 analysed, meal result, p value, event rates, well-tolerated conclusion, study limits, and no-significant-difference conclusion. PubMed XML lists Research Support, Non-U.S. Gov't; checked 2026-08-30.
- ↑ a b c d Helsinn Therapeutics. NCT00672074 registry record. ClinicalTrials.gov. NCT00672074. Used for sponsor, phase, enrolment, condition, and no posted results section. Checked 2026-08-30.
- ↑ a b c d e f Helsinn Therapeutics. NCT01280344 registry record. ClinicalTrials.gov. NCT01280344. Used for 320 actual enrolment, phase, sponsor, date, missing results, condition, and registry dose gap. Checked 2026-08-30.
- ↑ a b c Axial Therapeutic Research. Trifecta Research Study. ClinicalTrials.gov. NCT07717866. Used for study type, 52 actual enrolment, conditions, sponsor, bundled supplement list, and non-isolation limit. Checked 2026-08-30.
- ↑ a b c NLM. Exact PubMed clinical-trial search for the CJC pair, run 2026-08-30. Used for the controlled-combo absence. Checked 2026-08-30.
- ↑ a b Johansen PB et al. Rat bone-growth study. Growth Horm IGF Res, 1999. PMID 10373343. DOI 10.1054/ghir.1999.9998. Used for rat bone growth, body-weight gain, IGF-I limit, and future-human-study statement. Novo Nordisk affiliation and no PubMed XML grant checked 2026-08-30.
- ↑ a b c d Venkova K et al. Rodent bowel model. J Pharmacol Exp Ther, 2009. PMID 19289567. DOI 10.1124/jpet.108.149211. Used for rodent transit, fecal output, food intake, body-weight findings, and model limit. No grant in PubMed XML; checked 2026-08-30.
- ↑ a b c d e f g United States FDA. Compounding substances with safety concerns. FDA. FDA compounding page. Used for 503B category 2 placement, withdrawn-nominations placement, compounding concerns, and literature-study serious-event statement. Checked 2026-08-30.
- ↑ a b c d NLM. DailyMed exact search. Used for US label-search absence. Checked 2026-08-30.
- ↑ United States FDA. openFDA exact brand-name search. Used for exact brand-name application-search absence. Checked 2026-08-30.
- ↑ European Medicines Agency. Medicines output report. EMA medicines report. Used for central EU text-hit absence. Checked 2026-08-30.
- ↑ a b c d e Gajda PM et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal, 2019. PMID 30136411. DOI 10.1002/dta.2489. Used for seized-powder testing, analogue ID, N-terminal glycine change, source limit, and no-grant note. Checked 2026-09-05.
- ↑ a b c d e f Mendias CL, Awan TM. Research-grade peptide testing preprint. Preprints.org, 2026. Preprint manuscript. Used for voluntary testing reports, identity failures, manufactured-model pass rate, endotoxin subset, review status, funding, and conflicts. Checked against stored PDF evidence and manuscript page 2026-08-30.
- ↑ a b c d Mike Jason Pascual. CJC-1295 w/o DAC account. ExcelMale, 2014. ExcelMale thread. Used for one self-report, source-reported amounts, workouts, sleep, flushing, and product-verification limit. Checked 2026-08-30.
- ↑ a b Reddit users. Not every Peptide is for You!. r/Peptidesource, 2025. Reddit thread. Used for opened direct self-reports on CJC/Ipa, tesamorelin, positives, fat-loss uncertainty, and rash. Checked 2026-08-30.
- ↑ a b Siserman CV et al. Autopsied COVID-19 death in a young male bodybuilder. Medicina, 2022. PMID 36295534. DOI 10.3390/medicina58101373. Used for the single indexed case report naming the peptide, other-substance context, and author attribution away from the peptide. No grant in PubMed XML and no conflict declared; checked 2026-08-30.